Evidence map›Paper›PMID 35771301›Full record

ArticleInvestigational new drugs2022

Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.

Yu Sunakawa, Keishiro Takahashi, Osamu Kawaguchi, Nobuyuki Yamamoto

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00545246 (A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administered Every 3 Weeks in Patients With Advanced Solid Malignancies), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00545246 phase1completednot on this map

A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administered Every 3 Weeks in Patients With Advanced Solid Malignancies

TypeinterventionalSponsorSanofiRan2007 to 2012Enrolled12ConditionsNeoplasmsArmsaflibercept (AVE0005), docetaxel
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yu SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Keishiro TakahashiResearch & Development, Sanofi, Tokyo, Japan.
Osamu KawaguchiBiostatistics & Programming, Sanofi, Tokyo, Japan.
Nobuyuki YamamotoThird Department of Internal Medicine, Wakayama Medical University Hospital, Wakayama, Japan. nbyamamo@wakayama-med.ac.jp.
Sanofi (Japan) · JPSt. Marianna University School of Medicine · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis is a hallmark of cancer development. This study sought to determine the recommended dose of aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B and placental growth factor (PlGF), combined with docetaxel in Japanese patients with advanced solid malignancies. This phase I study was planned to include 12 patients following a 3 + 3 algorithm to determine the maximum tolerated dose of aflibercept combined with docetaxel in patients with metastatic or unresectable solid tumors (trial registration: NCT00545246). Docetaxel (75 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoplasmsDocetaxelFebrile NeutropeniaFemaleGranulocyte Colony-Stimulating FactorHumansJapanPlacenta Growth FactorReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AafliberceptDocetaxelGranulocyte Colony-Stimulating FactorPlacenta Growth FactorReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptDocetaxelDose escalationJapaneseVEGF Trap

Identifiers

PMID35771301
PMCPMC9395466
OpenAlexW4283754843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.